Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2019 Filed Feb 27, 2019 00:10 UTC |
ROGERS DAWNExecutive Vice President
|
Exercise / conversionCommon Stock | 19,290 | $21.03 | $405,668.70 |
DisclosureSEC source: 0001225208-19-003774 · doc4.xml · nonDerivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:11 UTC |
GOETTLER MICHAELGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 19,290 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003775 · doc4.xml · derivative · entry 5 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,290 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:11 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 6,007 | $41.91 | $251,753.37 |
DisclosureSEC source: 0001225208-19-003775 · doc4.xml · nonDerivative · entry 3 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,423 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:11 UTC |
GOETTLER MICHAELGroup President
|
Tax withholdingCommon Stock | 5,077 | $42.96 | $218,107.92 |
DisclosureSEC source: 0001225208-19-003775 · doc4.xml · nonDerivative · entry 2 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,430 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:11 UTC |
GOETTLER MICHAELGroup President
|
Exercise / conversionCommon Stock | 19,290 | $21.03 | $405,668.70 |
DisclosureSEC source: 0001225208-19-003775 · doc4.xml · nonDerivative · entry 1 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 43,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003777 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,724 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 13,615 | $41.91 | $570,604.65 |
DisclosureSEC source: 0001225208-19-003777 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,823 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 11,343 | $42.96 | $487,295.28 |
DisclosureSEC source: 0001225208-19-003777 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,438 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 43,724 | $21.03 | $919,515.72 |
DisclosureSEC source: 0001225208-19-003777 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,781 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 18,004 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003779 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,004 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 5,606 | $41.91 | $234,947.46 |
DisclosureSEC source: 0001225208-19-003779 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,324 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 4,252 | $42.96 | $182,665.92 |
DisclosureSEC source: 0001225208-19-003779 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,930 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 18,004 | $21.03 | $378,624.12 |
DisclosureSEC source: 0001225208-19-003779 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,182 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionStock Appreciation Rights · Derivative | 43,724 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003778 · doc4.xml · derivative · entry 6 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,724 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 13,615 | $41.91 | $570,604.65 |
DisclosureSEC source: 0001225208-19-003778 · doc4.xml · nonDerivative · entry 3 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,549 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
YOUNG JOHN DGroup President
|
Tax withholdingCommon Stock | 11,239 | $42.96 | $482,827.44 |
DisclosureSEC source: 0001225208-19-003778 · doc4.xml · nonDerivative · entry 2 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 301,164 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
YOUNG JOHN DGroup President
|
Exercise / conversionCommon Stock | 43,724 | $21.03 | $919,515.72 |
DisclosureSEC source: 0001225208-19-003778 · doc4.xml · nonDerivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 36,008 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003780 · doc4.xml · derivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,008 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 11,212 | $41.91 | $469,894.92 |
DisclosureSEC source: 0001225208-19-003780 · doc4.xml · nonDerivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,477 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Tax withholdingCommon Stock | 8,749 | $42.96 | $375,857.04 |
DisclosureSEC source: 0001225208-19-003780 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,689 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 36,008 | $21.03 | $757,248.24 |
DisclosureSEC source: 0001225208-19-003780 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 87,449 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003781 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,449 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 27,230 | $41.91 | $1,141,209.30 |
DisclosureSEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,803 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 25,991 | $42.96 | $1,116,573.36 |
DisclosureSEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,033 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionCommon Stock | 87,449 | $21.03 | $1,839,052.47 |
DisclosureSEC source: 0001225208-19-003781 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 185,185 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003782 · doc4.xml · derivative · entry 4 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,185 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 58,983 | $42.96 | $2,533,909.68 |
DisclosureSEC source: 0001225208-19-003782 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 405,930 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F5 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 57,663 | $41.91 | $2,416,656.33 |
DisclosureSEC source: 0001225208-19-003782 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 464,913 F2 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F3 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:45 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 185,185 | $21.03 | $3,894,440.55 |
DisclosureSEC source: 0001225208-19-003782 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:46 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 97,737 | $0.00 Strike: $21.03 | $0.00 |
DisclosureSEC source: 0001225208-19-003783 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,737 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:46 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 32,420 | $42.96 | $1,392,763.20 |
DisclosureSEC source: 0001225208-19-003783 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,980 F4 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F5 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:46 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 30,433 | $41.91 | $1,275,447.03 |
DisclosureSEC source: 0001225208-19-003783 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,400 F2 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F3 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 00:46 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 97,737 | $21.03 | $2,055,409.11 |
DisclosureSEC source: 0001225208-19-003783 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 01:17 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 54,568 | $42.96 | $2,344,241.28 |
DisclosureSEC source: 0001225208-19-003785 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,078 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 23, 2019 Filed Feb 27, 2019 01:17 UTC |
READ IAN CDirector · Executive Chairman
|
Tax withholdingCommon Stock | 193,170 | $42.96 | $8,298,583.20 |
DisclosureSEC source: 0001225208-19-003786 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,586,737 F1 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). F2 · price: Price is the closing price of Pfizer common stock on February 22, 2019 Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 22:51 UTC |
BOURLA ALBERTDirector · Chief Executive Officer
|
GrantPhantom Stock Units SSP · Derivative | 299 | $41.68 | $12,462.32 |
DisclosureSEC source: 0001225208-19-002321 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,079 Underlying: Common Stock · 299 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 22:51 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 71 | $41.68 | $2,959.28 |
DisclosureSEC source: 0001225208-19-002322 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,776 Underlying: Common Stock · 71 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 22:51 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 747 | $41.68 | $31,134.96 |
DisclosureSEC source: 0001225208-19-002323 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,496 Underlying: Common Stock · 747 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 11, 2019 Filed Feb 12, 2019 22:52 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 424 | $41.68 | $17,672.32 |
DisclosureSEC source: 0001225208-19-002324 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,166 Underlying: Common Stock · 424 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:17 UTC |
DAMELIO FRANK AExecutive Vice President
|
OtherPhantom Stock Units SSP · Derivative | 42,690 | $42.44 | $1,811,763.60 |
DisclosureSEC source: 0001225208-19-001863 · doc4.xml · derivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,690 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F3 · shares: This transaction constitutes an intra-plan transfer involving the Pfizer stock unit fund under the Pfizer Inc. Supplemental Savings Plan. F4 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F4 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:17 UTC |
DAMELIO FRANK AExecutive Vice President
|
OtherCommon Stock | 5,182 | $42.44 | $219,924.08 |
DisclosureSEC source: 0001225208-19-001863 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Rule 16b-3 Plan Disclosed balance after: 0 F1 · shares: This transaction constitutes an intra-plan transfer involving the Pfizer stock fund under the Company's Qualified Savings Plan. Read SEC document |
| February 01, 2019 Filed Feb 2, 2019 00:21 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 5,000 | $42.75 | $213,750.00 |
DisclosureSEC source: 0001225208-19-001685 · doc4.xml · nonDerivative · entry 9 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,057 Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 00:28 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 164,534 | $27.37 Strike: $27.37 | $4,503,295.58 |
DisclosureSEC source: 0001225208-19-001686 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 164,534 shares Expires 2020-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 00:28 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 144,928 | $34.59 Strike: $34.59 | $5,013,059.52 |
DisclosureSEC source: 0001225208-19-001686 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 144,928 shares Expires 2020-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 00:28 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 42,061 | $34.59 | $1,454,889.99 |
DisclosureSEC source: 0001225208-19-001686 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.14)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| January 31, 2019 Filed Feb 2, 2019 00:28 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 83,907 | $27.37 | $2,296,534.59 |
DisclosureSEC source: 0001225208-19-001686 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price of $42.14)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:21 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 17,099 | $41.19 | $704,307.81 |
DisclosureSEC source: 0001225208-19-001685 · doc4.xml · nonDerivative · entry 8 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,057 Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:21 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 9,136 | $41.20 | $376,403.20 |
DisclosureSEC source: 0001225208-19-001685 · doc4.xml · nonDerivative · entry 7 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,156 Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:21 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 6,000 | $41.18 | $247,080.00 |
DisclosureSEC source: 0001225208-19-001685 · doc4.xml · nonDerivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,292 Read SEC document |
| January 30, 2019 Filed Feb 2, 2019 00:21 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
SaleCommon Stock | 2,100 | $41.16 | $86,436.00 |
DisclosureSEC source: 0001225208-19-001685 · doc4.xml · nonDerivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,292 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.